Haley Laken

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan et al. · Clinical Cancer Research · 2022 · 97 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131

Lex Van der Ploeg, Haley Laken, Shubh D. Sharma et al. · Life Sciences · 2014 · 53 citations

Medicine, Endocrinology, Pharmacology +12

Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody

A. Murtaza, Haley Laken, Jean da Silva Correia et al. · European Journal of Cancer · 2016 · 33 citations

Pharmacy, Immunology, Medicinal Chemistry +10

Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody

Haley Laken, Marilyn R. Kehry, Patricia McNeeley et al. · European Journal of Cancer · 2016 · 23 citations

Pharmacy, Immunology, Oncology +12

Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.

Glen J. Weiss, Jasgit C. Sachdev, Jeffrey R. Infante et al. · Journal of Clinical Oncology · 2014 · 14 citations

Medicine, Oncology, Pharmacology +17